India Aligns Drug Manufacturing Norms with WHO Standards While Granting MSME Relief

In a strategic move to bolster pharmaceutical quality without stifling smaller manufacturers, the Drugs Technical Advisory Board (DTAB) has refined the implementation of the revised Schedule M. The decisions, made during the board’s 93rd meeting on March 23, 2026, focus on harmonizing Indian standards with global benchmarks.

Stricter Sterility for High-Risk Drugs

The DTAB approved a critical amendment to tighten microbial contamination limits for “Grade A” manufacturing areas—the ultra-sterile zones where injectables and vaccines are processed.

By aligning these limits with the World Health Organization (WHO) Technical Report Series (TRS) 1044, India is ensuring that its “Grade A” environments meet the same rigorous safety criteria used by international regulators. This move is expected to significantly reduce the risk of contamination in life-saving medicines and improve the global acceptance of Indian exports.

Pragmatic Exemptions for Lower-Risk Categories

While raising the bar for sterile drugs, the board acknowledged that a “one-size-fits-all” approach could create an unnecessary compliance burden for specific industries.

To support ease of doing business, the DTAB recommended continuing the earlier exemptions for:

Medical Gases (e.g., Oxygen, Nitrous Oxide)
Empty Gelatin Capsules
Disinfectant Fluids

These categories will not be required to meet the full suite of the new Schedule M infrastructure upgrades, as their manufacturing processes pose a lower risk to patient safety compared to systemic drugs.

A Balanced Regulatory Future

These updates follow the landmark G.S.R. 922(E) notification from late 2023. By combining strict global microbial standards with targeted industry relief, the DTAB aims to transform India from the “Pharmacy of the World” into the “Quality Pharmacy of the World.”